Lebrikizumab companion diagnostic - Roche
Latest Information Update: 20 Oct 2016
At a glance
- Originator Roche
- Class Diagnostic agents
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Phase III Asthma
Most Recent Events
- 20 Oct 2016 Phase-III development is ongoing in USA
- 02 Feb 2011 Phase-II clinical trials in Asthma (Diagnosis) in USA (Roche companion diagnostics pipeline, February 2011)